Connor, Clark & Lunn Investment Management (CC&L)
KDNY

Connor, Clark & Lunn Investment Management (CC&L)’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-170,211
Closed -$3.94M – 1563
2023
Q1 		$3.94M Sell
170,211
-65,605
-28% -$1.56M 0.02% 415
2022
Q4 		$6.18M Sell
235,816
-51,468
-18% -$1.14M 0.04% 311
2022
Q3 		$5.65M Buy
287,284
+166,342
+138% +$3.34M 0.04% 301
2022
Q2 		$2.12M Buy
120,942
+94,795
+363% +$1.49M 0.01% 459
2022
Q1 		$428K Buy
26,147
+5,881
+29% +$80K ﹤0.01% 810
2021
Q4 		$331K Buy
+20,266
New +$288K ﹤0.01% 872
2020
Q2 		– Sell
-7,822
Closed -$107K – 1210
2020
Q1 		$107K Sell
7,822
-29,814
-79% -$353K ﹤0.01% 926
2019
Q4 		$222K Buy
37,636
+28,937
+333% +$157K ﹤0.01% 820
2019
Q3 		$46K Sell
8,699
-280
-3% -$1.86K ﹤0.01% 936
2019
Q2 		$69K Buy
8,979
+2,264
+34% +$34.5K ﹤0.01% 960
2019
Q1 		$134K Buy
+6,715
New +$117K ﹤0.01% 853

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s KDNY Position: Q2 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 170,211 shares — an estimated $3.94M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KDNY in Q1 2019 and held it in 11 quarters. The position peaked at $6.18M in Q4 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 170,211 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $3.94M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2019 and held it in 11 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Chinook Therapeutics, Inc. Common Stock position peaked at $6.18M in Q4 2022.
  • 185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2023, filed 10 Aug 2023.